Arca
Skip to content
Tools
Tools

Hereditary hemorrhagic telangiectasia

Drug research and approvals for hereditary hemorrhagic telangiectasia: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 17 studies of hereditary hemorrhagic telangiectasia are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, and FDA has 0 approved and 7 open orphan designations naming it.

  • Recruiting worldwide: 17
  • Trials authorized in Canada: 0
  • FDA orphan approvals: 0
  • EU medicines: 0

Recruiting now

Newest posted first, of 17 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Phase 3 4

Phase 2 7

  • PomalidomideCRL4(CRBN) E3 ubiquitin ligase inhibitor
  • TimololBeta-1 adrenergic receptor antagonist
  • NintedanibPlatelet-derived growth factor receptor inhibitor
  • DoxycyclineMatrix metalloproteinase 7 inhibitor
  • PazopanibMacrophage colony stimulating factor receptor inhibitor
  • TamoxifenEstrogen receptor alpha modulator
  • OctreotideSomatostatin receptor agonist

Phase 1 or earlier 1

How its trials ended

82 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 16 whose ending is known, 44% met their primary endpoint, 19% missed it and 38% stopped early.

  • Completed, result not reported4150%
  • Ongoing1822%
  • Met its primary endpoint79%
  • Status unknown79%
  • Stopped: other or unclear45%
  • Missed its primary endpoint34%
  • Stopped: sponsor or business decision22%

FDA orphan designations

Approved first, then open designations, newest first
Jun 9, 2025BMPRII: ALK1 bispecific clustering agonist antibodyTreatment of hereditary hemorrhagic telangiectasiaDiagonal TherapeuticsDesignated
Dec 7, 20226-(4-((1s,3s)-1-amino-3-hydroxycyclobutyl)…Treatment of Hereditary Hemorrhagic TelangiectasiaVaderis Therapeutics AGDesignated
Oct 12, 2022BevacizumabTreatment of hereditary hemorrhagic telangiectasiaLaboratoires Delbert SASDesignated
Oct 9, 2019PazopanibTreatment of hereditary hemorrhagic telangiectasiaHHT Foundation International (d/b/a Cure HHT)Designated
Jul 19, 2017ThalidomideTreatment of hereditary hemorrhagic telangiectasiaPlumeStars s.r.l.Designated
Oct 21, 2010BevacizumabTreatment of hereditary hemorrhagic telangiectasiaTerence M. Davidson, MDDesignated
Aug 20, 2010Raloxifene hydrochlorideTreatment of hereditary hemorrhagic telangiectasiaConsejo Superior de Investigaciones CientificasDesignated

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.